Skip to content

Clinical trials

Attention Deficit Disorder with Hyperactivity trials in Denmark

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Attention Deficit Disorder with Hyperactivity Country / region: Denmark Clear all

29 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20081
20091
20103
20111
20122
20131
20141
20162
20171
20182
20191
20201
20211
20222
20231
20243
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13
Unknown status10
Recruiting3
Enrolling by invitation2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Aarhus7
Region Syddanmark3
Novartis Pharmaceuticals2
University Hospital Bispebjerg and Frederiksberg2
University of Southern Denmark2
Aalborg University1
Aarhus University Hospital1
Allan Hvolby1
Behandlingsskolerne1
Copenhagen University Hospital at Herlev1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Attention Deficit Disorder with Hyperactivity29
Autism Spectrum Disorder3
Parasomnias3
Anxiety Disorders2
Bipolar Disorder2
Mental Disorders2
Arrhythmias, Cardiac1
Asperger Syndrome1
Cardiovascular Abnormalities1
Cardiovascular Diseases1

Trials

Showing 51 to 29 of 29. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.